The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
Open accessPublished version of a preprint
Abstract
BACKGROUND: The relationship between the presence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the risk of subsequent reinfection remains unclear. METHODS: We investigated the incidence of SARS-CoV-2 infection confirmed by polymerase chain reaction (PCR) in seropositive and seronegative health care workers attending testing of asymptomatic and symptomatic staff at Oxford University Hospitals in the United Kingdom. Baseline antibody status was determined by anti-spike (primary analysis) and anti-nucleocapsid IgG assays, and staff members were followed for up to 31 weeks. We estimated the relative incidence of PCR-positive test results and new symptomatic infection according to antibody status, adjusting for age, participant-reported gender, and changes in incidence over time. RESULTS: A total of 12,541 health care workers participated and had anti-spike IgG measured; 11,364 were followed up after negative antibody results and 1265 after positive results, including 88 in whom seroconversion occurred during follow-up. A total of 223 anti-spike-seronegative health care workers had a positive PCR test (1.09 per 10,000 days at risk), 100 during screening while they were asymptomatic and 123 while symptomatic, whereas 2 anti-spike-seropositive health care workers had a positive PCR test (0.13 per 10,000 days at risk), and both workers were asymptomatic when tested (adjusted incidence rate ratio, 0.11; 95% confidence interval, 0.03 to 0.44; P = 0.002). There were no symptomatic infections in workers with anti-spike antibodies. Rate ratios were similar when the anti-nucleocapsid IgG assay was used alone or in combination with the anti-spike IgG assay to determine baseline status. CONCLUSIONS: The presence of anti-spike or anti-nucleocapsid IgG antibodies was associated with a substantially reduced risk of SARS-CoV-2 reinfection in the ensuing 6 months. (Funded by the U.K. Government Department of Health and Social Care and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This study estimated that seropositivity at enrolment reduced the incidence of detected reinfection by almost 89% over a median follow-up of 139 days.”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [53]
In the citing paper
“a level of protection that is not significantly different to the 89–95% protection that has been estimated following natural infection53,54.”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [53]
In the citing paper
“Preexisting immunity to SARS-CoV-2 is associated with protection against reinfection in humans (9–11) and in nonhuman primates (12, 13).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
To, K. K., Tsang, O. T.-Y., Leung, W.-S., Tam, A. R., Wu, T.-C., Lung, D. C., Yip, C. C., Cai, J., Chan, J. M., Chik, T. S., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30196-1 · Cited by 3,045
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
Wajnberg, A., Amanat, F., Firpo, A., Altman, D. R., Bailey, M. J., Mansour, M., McMahon, M., Meade, P., Mendu, D. R., Muellers, K., et al. (2020) · Science · doi:10.1126/science.abd7728 · Cited by 1,195
Humoral Immune Response to SARS-CoV-2 in Iceland
Gudbjartsson, D. F., Norddahl, G. L., Melsted, P., Gunnarsdottir, K., Holm, H., Eythorsson, E., Arnthorsson, A. O., Helgason, D., Bjarnadottir, K., Ingvarsson, R. F., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2026116 · Cited by 903
Vaccines: Correlates of Vaccine‐Induced Immunity
Plotkin, S. A. (2008) · Clinical Infectious Diseases · doi:10.1086/589862 · Cited by 829
Genomic evidence for reinfection with SARS-CoV-2: a case study
Tillett, R. L., Sevinsky, J. R., Hartley, P. D., Kerwin, H., Crawford, N. F., Gorzalski, A. J., Laverdure, C., Verma, S. C., Rossetto, C. C., Jackson, D. K., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30764-7 · Cited by 755
To, K. K.-W., Hung, I. F.-N., Ip, J. D., Chu, A. W.-H., Chan, W.-M., Tam, A. R., Fong, C. H.-Y., Yuan, S., Tsoi, H.-W., Ng, A. C.-K., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1275 · Cited by 746
Addetia, A., Crawford, K. H. D., Dingens, A., Zhu, H., Roychoudhury, P., Huang, M.-L., Jerome, K. R., Bloom, J. D., & Greninger, A. L. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.02107-20 · Cited by 525
Flagged first, then by citations
Research works printed but not linked: 2
- Muecksch F, Wise H, Batchelor B, et al. Longitudinal analysis of serology and neutralizing antibody levels in COVID19 convalescents. J Infect Dis 2020 November 3 (Epub ahead of print).33140086
- To KK-W, Hung IF-N, Ip JD, et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clin Infect Dis 2020 August 25 (Epub ahead of print).32840608
Cited by
Sorted by citations
Items 701–800 of 913
A deconvolution approach to modelling surges in COVID-19 cases and deaths
Melnyk, A., Kozarov, L., & Wachsmann‐Hogiu, S. (2022) · Scientific Reports · doi:10.1038/s41598-023-29198-4 · Cited by 2
Estimates of anti-SARS-CoV-2 antibody seroprevalence in Iran – Authors' reply
Darvishian, M., Sharafkhah, M., Poustchi, H., & Malekzadeh, R. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00058-x · Cited by 2
Karaca, A., Günçıkan, M. N., Sözmen, N. N., Karadağ, G. G., & Yılmaz, M. (2021) · Medeniyet Medical Journal · doi:10.5222/mmj.2021.00921 · Cited by 1
Friedman, S. M., Li, J., Thomas, P., Gurumurthy, M., Siderits, R. H., Nepomich, A., & Lifshitz, E. I. (2022) · Journal of Community Health · doi:10.1007/s10900-022-01142-z · Cited by 1
Yoshikawa, M., Natori, Y., Oki, R., Unagami, K., Ohfuji, S., Imamura, R., Ishida, H., Takahara, S., Hirota, Y., & Egawa, H. (2023) · Scandinavian Journal of Immunology · doi:10.1111/sji.13308 · Cited by 1
Ningsih, D. M., Firmansyah, M. T., & Wawo, B. A. M. (2023) · Journal of World Future Medicine Health and Nursing · doi:10.55849/health.v1i1.431 · Cited by 2
Oliveira, M. D. S., Carvalho, R. F., Meurer, C. M., Rodrigues, É. M., Dias, B. P., dos Santos, I. G. C., Nascimento, C. A., Rodrigues, Y. M., dos Santos, A. J. F., Almeida, K. D. S., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0300191 · Cited by 1
Manteghinejad, A., Rasti, S., Nasirian, M., & Javanmard, S. H. (2024) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_173_23 · Cited by 1
Rop, L. D., Vercruysse, H., Alenus, U., Brusselmans, J., Callens, S. F. J., Claeys, M., Coene, N. D., Persyn, P., Padalko, E. Y., Heytens, S., et al. (2024) · Viruses · doi:10.3390/v16091461 · Cited by 1
SARS-CoV-2 Immunization Index in the Academic Community: A Retrospective Post-Vaccination Study
Oliveira, K., Almeida, A., Silva, C., Brito, M., & Ribeiro, E. (2024) · Infectious Disease Reports · doi:10.3390/idr16060088 · Cited by 1
Sikuvi, K., Nghitukwa, N., Kakehongo, N., Katjitae, I., Matos, C., Oedi, P., Netha, S., Nepolo, E., & Winter, C. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.126977 · Cited by 1
Zheng, X., Chen, Q., Liao, Q., & Zhang, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1533102 · Cited by 1
Hybrid Immunity in a Mozambican Cohort After 1 or 2 Doses of the BBIBP-CorV Vaccine
Chissumba, R. M., Kwatra, G., Ramgi, P., Enosse, M., Sigaúque, A., Khosa, C., Viegas, E., Bule, O., Langa, J. P., Dhar, N., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf095 · Cited by 1
Sirakov, I. N., Shishkova, K., Shishkov, S., & Alexiev, I. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47110919 · Cited by 2
SECCION I. Antecedentes de infección por SARS-CoV-2/COVID-19
Trujillo, C. H. S. (2021) · Infectio · doi:10.22354/in.v25i4.971 · Cited by 1
Kushima, H., Ishii, H., Kinoshita, Y., Koide, Y., Komiya, Y., Kato, J., Umehara, M., Sakata, M., Miyazaki, M., & Ikuta, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11185388 · Cited by 1
King, H. A. D., Dussupt, V., Mendez-Rivera, L., Slike, B. M., Tran, U., Jackson, N. D., Barkei, E. K., Zemil, M., Tourtellott‐Fogt, E., Kuklis, C. H., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1138629 · Cited by 1
Abdullah, Z. M., Goreal, A. A., & Abdo, J. M. (2023) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.17372 · Cited by 1
Ören, M. M., Canbaz, S., Meşe, S., Ağaçfidan, A., Demir, Ö. F., Karaca, E., Doğruyol, A. R., Otcu, G. H., Tükek, T., & Özgülnar, N. (2023) · Vaccines · doi:10.3390/vaccines11050935 · Cited by 1
SARS-CoV-2 Reinfection Rate: A Systematic Review and Meta-analysis
Alimohamadi, Y., Bahani, K., Alimohamadi, K., & Sepandi, M. (2023) · Infection Epidemiology and Microbiology · doi:10.52547/iem.9.1.63 · Cited by 1
Fíca, A., Olivares, F., Maritza Navarrete, C., Pizzi, G. M., Ulloa, M. M., Fuentevilla, K. C., Morales, T. C., Torres, N. M., Mejías, J. C. V., Palomino, D. L., et al. (2023) · Revista médica de Chile · doi:10.4067/s0034-98872023000100023 · Cited by 1
Romandhona, S. (2023) · Journal of World Future Medicine Health and Nursing · doi:10.55849/health.v1i1.430 · Cited by 1
Kotwica-Strzałek, E., Jędrych, E., Rymarz, A., Romejko, K., Smoszna, J., Korsak, J., Marczak, I., Gielerak, G. G., & Niemczyk, S. (2024) · Pediatria i Medycyna Rodzinna · doi:10.15557/pimr.2024.0026 · Cited by 1
COVID 19: Prevention and treatment through the Indian perspective
Chandra, H., Yadav, A., Prasad, R., Sagar, K., Bhardwaj, N., Gupta, K. K., Thakur, G. S., Nigam, M., Pezzani, R., de Lima, J. P. M., et al. (2024) · Cytokine · doi:10.1016/j.cyto.2024.156756 · Cited by 1
Time-course analysis of antibody and cytokine response after the third SARS-CoV-2 vaccine dose
Kim, H. H., Lee, H., Hennighausen, L. G., Furth, P. A., Sung, H., & Huh, J. W. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100565 · Cited by 1
Nurjaya, I., Arief, E., Tabri, N. A., Djaharuddin, I., Natsir, B., Nurisyah, S., Hendarto, J., Ansariadi, A., Rasiha, R., & Makkaraka, M. A. G. (2024) · Exploration of Immunology · doi:10.37349/ei.2024.00166 · Cited by 1
Pan, J., Zhang, X.-D., Shi, D., Tian, X., Xu, L., Lu, X., Dong, M., Peng, Y., Pan, Z., Ling, Z., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-82596-0 · Cited by 1
Sivo, D., Russo, A., Daliani, P. L., Maselli, C., Balzano, A., Carelli, D., Durante, P., Basile, V., Rizzo, A., Stilla, A., et al. (2021) · Journal of Advanced Health Care · doi:10.36017/jahc202133179 · Cited by 1
The front-line during the coronavirus disease 2019 pandemic: healthcare personnel
Kang, M., & Perl, T. M. (2021) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000734 · Cited by 1
van Bremen, K., Monin, M. B., Eis‐Hübinger, A. M., Marx, B., Aldabbagh, S., Streeck, H., Wasmuth, J., Menting, T., Schlabe, S., Rieke, G. J., et al. (2021) · Infection · doi:10.1007/s15010-021-01641-6 · Cited by 1
Rzepliński, R., Szymański, P., Hamer, K., Zdziebko, M., Szarowska, A., Korcz, T., Zaczyński, A., Król, Z. J., & Wierzba, W. (2021) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16025 · Cited by 1
Hawaldar, R., Sodani, S., Sodani, V., & Sodani, R. K. (2021) · The Journal of Community Health Management · doi:10.18231/j.jchm.2021.017 · Cited by 1
SARS-CoV-2 Variants: Past, Present and Future
Peacock, S. J. (2021) · Economics, law, and institutions in Asia Pacific · doi:10.1007/978-981-16-5727-6_1 · Cited by 2
SARS-CoV-2 RT-PCR Pozitif Sağlık Çalışanlarında Serokonversiyon Durumunun Boylamsal İzlenmesi
Ersoy, L., Ülger, S. T., GÜLBUDAK, H., Yaşar, N., Yapıcı, G., & Aslan, G. (2022) · Mikrobiyoloji Bulteni · doi:10.5578/mb.20229910 · Cited by 1
Sonié, P., Manuel-Silva, J., Rafael, A., & Alves, L. (2022) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1490_21 · Cited by 1
Immunology in COVID-19; more than diagnosis of infection or the basis of vaccination
Egri, N., & Juan, M. (2022) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2021.11.005 · Cited by 1
Hussein, R. M., & Lami, F. (2022) · Iproceedings · doi:10.2196/36473 · Cited by 1
The Early-Term Adverse Effects in Healthcare Personnel after CoronaVac Vaccination
Çil, B., & Kabak, M. (2022) · Journal of Contemporary Medicine · doi:10.16899/jcm.1026942 · Cited by 1
Fatores de virulência microbianos e terapias emergentes
Barbosa, A. V., da Silva, S. M., da Silva, F. H. S., de Assunção, M. A. S., & dos Anjos, F. B. R. (2022) · Latin American Publicações eBooks · doi:10.47174/lap2020.ed.0000093 · Cited by 2
SARS-CoV-2 seroprevalence among healthcare personnel at a large health system in Atlanta
Graciaa, D. S., Kempker, R. R., Wang, Y. F., Schurr, H., Krishnan, S. D., Carroll, K., Toomer, L., Merritt, S., King, D., Hunter, M., et al. (2022) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2022.04.009 · Cited by 1
Results of screening examination of employees of a medical hospital for antibodies to SARS-CoV-2
Sayfullin, R. F., Константиновна, П. С., & Ованесович, С. Д. (2022) · Infectious diseases News Opinions Training · doi:10.33029/2305-3496-2022-11-1-28-33 · Cited by 1
Development and Evaluation about “2nd-wave” COVID-19 Vaccines
Araki, Y. (2022) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.21-00234-3 · Cited by 1
Amanat, A., Lankarani, K. B., Honarvar, B., Asmarian, N., Shokripour, M., Rafiee, F., Ghadim, M. B. A., Izadi, F., Omidifar, N., & Dorraninejad, S. A. (2022) · Shiraz E-Medical Journal · doi:10.5812/semj-121681 · Cited by 1
Asadi-Samani, M., Soltani, M., Altememy, D., Imani, F., Moradi, M.-T., Kheiri, S., & Asadi-Samani, F. (2022) · Immunopathologia Persa · doi:10.34172/ipp.2022.33411 · Cited by 1
Pros and Cons for COVID-19 Vaccination and Boost of Young Adults in Light of Recent Literature
Nemunaitis, J. J., Lehmann, P., & Willey, J. C. (2022) · Medical Research Archives · doi:10.18103/mra.v10i8.2943 · Cited by 1
FEATURES OF THE COURSE OF COVID-19 IN DIFFERENT TIME PERIODS
Павлович, Г. Г., Nikitina, V. V., Ivanenko, I. L., Zakharova, N. B., Maksimova, L. V., Pavlova, N. N., Shirokova, S. S., & Веретенников, С. И. (2022) · Современные проблемы науки и образования · doi:10.17513/spno.31903 · Cited by 1
Suljič, A., Sočan, M., Mrzel, M., Lunar, M. M., Korva, M., Štorman, A., Prosenc, K., Janežič, S., Čretnik, T. Ž., Zupanič, T., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.962653 · Cited by 1
Durability of antibodies post vaccination with two doses of inactivated BBIBP-CorV vaccine
Mahmoud, S., Ganesan, S., Sharif‐Askari, N. S., Cantarutti, F. M., Wilson, H. V., Ogrodzki, P., Halwani, R., Kaabi, N. A., & Zaher, W. A. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2139969 · Cited by 1
García, S. L. B. (2022) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001599 · Cited by 1
Silva, N. D. L., da Silva, D. N., de Oliveira, J. A., Rezende, M. S., dos Santos, J. T. D. C., Araújo, A. A. D. S., Quintans‐Júnior, L. J., Cavalcante, R. C. M., Ferreira, L. C. D. S., Martins‐Filho, P. R., et al. (2022) · EXCLI journal · doi:10.17179/excli2022-5337 · Cited by 1
Yurtsever, İ., Karatoprak, C., Sümbül, B., Kıskaç, M., Tunç, M., Zorlu, M., Ogün, H., Durdu, B., Toluk, Ö., & Çakırca, M. (2022) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.20220921 · Cited by 1
COVID-19 Relapse and Reinfection Frequency, Clinical Features of Cases
Aslaner, H., Aslaner, H. A., Savranlar, Y., & Benli, A. R. (2022) · Ahi Evran Medical Journal · doi:10.46332/aemj.1005961 · Cited by 1
Grujić, J., Bujandrić, N., Budakov-Obradović, Z., Savic, N., & Dolinaj, V. (2022) · Vojnosanitetski pregled · doi:10.2298/vsp210301094g · Cited by 1
Tameshkel, F. S., Dargoush, S. A., Amirkalali, B., Javadi, S., Ghiaseddin, A., Alimohamadi, Y., Basi, A., Makiani, M. J., Zamani, F., & Niya, M. H. K. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2022.1095194 · Cited by 1
COVID-19 Antibody Response in Patients with Thalassemia
Kumari, N., Gomber, S., Dewan, P., Narang, S., & Ahmed, R. S. (2023) · Cureus · doi:10.7759/cureus.40567 · Cited by 1
Mallmann, T. Y., da Silva, E. S., Sanches, R. D. P. M., da Silva, R. R., de Oliveira, T. C., Silva, C. S. B., Fernandes, E. R. D. Q. G. D. S. E., & Matos, M. M. M. (2022) · Revista do Hospital Universitário Getúlio Vargas · doi:10.60104/revhugv10026 · Cited by 1
SARS-CoV-2 reinfections in the pediatric cohort—a single-center experience
Arslan, A., Bal, Z. Ş., Erci, E., Arslan, S. Y., Bilen, N. M., Avcu, G., Çiçek, C., Özkınay, F., & Kurugöl, Z. (2023) · Journal of Tropical Pediatrics · doi:10.1093/tropej/fmad049 · Cited by 1
How to Advise Persons Who Are Antibody Positive for SARS-CoV-2 About Future Infection Risk
Katz, M. H. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.0374 · Cited by 1
Hunziker, P. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3780070 · Cited by 1
Gehring, S., Okasha, O., Kowalzik, F., Engelmann, T., Schreiner, D., Jensen, C., Mähringer‐Kunz, A., Hartig-Merkel, W., Tomer, A., Oostvogels, L., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-688656/v1 · Cited by 1
A simple, sensitive and quantitative FACS-based test for SARS-CoV-2 serology in humans and animalsPreprint
Ribes, A. M., Bessière, P., Guéry, J., Featherstone, E. J., Bruel, T., Robinot, R., Schwartz, O., Volmer, R., Abravanel, F., Izopet, J., et al. (2021) · medRxiv · doi:10.1101/2021.09.06.21262027 · Cited by 1
Gargouri, S., Abid, N., Karray, H., & Rebaï, A. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.01.059 · Cited by 1
Dobaño, C., Ramirez, A., Alonso, S., Vidal‐Alaball, J., Ruiz‐Olalla, G., Vidal, M., Rubio, R., Cascant, E., Parras, D., Melero, N. R., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-142984/v2 · Cited by 1
Grier, J. T. (2021) · The Conversation · doi:10.64628/aai.4tan6vn6g · Cited by 1
Conlon, C. P., & Firth, J. D. (2020) · Oxford University Press eBooks · doi:10.1093/med/9780198746690.003.0650
Self-citationSevere Acute Respiratory Syndrome Coronavirus 2 Episode 2? A Sequel Nobody Wants to See
Piantadosi, A. L. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab224
Védőoltások a Covid-19-pandémia ellen
Falus, A., & Szekanecz, Z. (2021) · Lege Artis Medicinae · doi:10.33616/lam.31.002
A Blueprint to Control the SARS-CoV-2 Pandemic
O’Horo, J. C., Williams, A. W., & Badley, A. D. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.03.013
Persistence of immunoglobulin G after natural infection with SARS-CoV-2
Kreuzberger, N., Hirsch, C., Vanshylla, K., Cristanziano, V. D., Dorando, E., Khosravi, Z., Neidhardt, M., Salomon, S., Monsef, I., Lange, B., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014946 · Cited by 1
Do Covid-19 antibodies provide protecting for over 6 months?
Deveci, Ö. (2020) · Biomedical Research and Clinical Practice · doi:10.15761/brcp.1000214
Richardson, C., Gildea, S., Harkin, S., Gallagher, A., Conroy, E., McClafferty, L., McCole, E., Benchikh, E. O., Reid, C. N., Dunlop, M., et al. (2021) · medRxiv · doi:10.1101/2021.06.03.21255116
López, E., Duarte, J., Grijalba, R., González, A., Cuenca, E., Enciso, A., Ríos, E., Galeano, M., Sánchez, S., González, L., et al. (2021) · Revista de salud publica del Paraguay · doi:10.18004/rspp.2021.junio.8 · Cited by 1
Daten & Fakten zur Impfbegleitung und Immunität
Ambrosch, A., & Braess, J. (2021) · Trillium Diagnostik · doi:10.47184/td.2021.02.03
Covid-19 Re-infection vs Prolonged Viral Shedding
Barohn, R. J., Hindle, M., Peck, L., & Naqvi, S. H. (2021) · RRNMF Neuromuscular Journal · doi:10.17161/rrnmf.v2i2.15057
Self-citationCOVID-19: Studie aus Oxford spricht für postinfektiöse Immunität
(2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1401-8509
Inflammatory Rebound in Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Farrokhnia, M., & Dalfardi, B. (2021) · Shiraz E-Medical Journal · doi:10.5812/semj.115220
Ikeda, K., Nakada, T., Kageyama, T., Tanaka, S., Yoshida, N., Ishikawa, T., Goshima, Y., Taniguchi, T., Igari, H., Hanaoka, H., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3903937
Longevity of SARS-CoV-2 Antibody in Health Care Workers: 6-Months Follow UpPreprint
Brant-Zawadzki, M. N., Fridman, D., Robinson, P. A., German, R., Shapiro, A., Breit, M., Wilton, S., Burke, E., Bock, J. R., & Hara, J. (2021) · medRxiv · doi:10.1101/2021.08.25.21262632
Hunziker, P. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3794249
The Evidence for COVID-19 and The Restrictions on Medical Education and Research
Kudo, A., & Okada, E. (2021) · Journal of Japan Society of Computer Aided Surgery · doi:10.5759/jscas.23.124
Williams, D. E. (2021) · Research Square · doi:10.21203/rs.3.rs-1051588/v1
Inmunidad humoral natural al año tras infección por SARS-CoV-2 en pacientes hospitalizados
Cabanes, L., Rubio, C., Martinez, O., & Naval, E. (2021) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2021.10.012
[Antithrombotic prophylaxis of the complications of arteriosclerosis obliterans].
Heine, H., Norden, K., Heinemann, L., Stepanauskas, M., & Schmidt, H. (1981) · PubMed
Critical Thinking and Hired Education: The Need for Life Long Learning.
McLaughlin, J. (2001) · WebNet
(2021) · Journal of Medical Case Reports and Case Series · doi:10.38207/jmcrcs/2021/0211171
Williams, D. E. (2021) · Research Square · doi:10.21203/rs.3.rs-1051588/v2
Fuse‐Nagase, Y., & Nagase, M. (2021) · medRxiv · doi:10.1101/2021.12.22.21268296
Homan, T., Fortunato, F., Corso, G., Lopalco, P. L., Prato, R., & Martinelli, D. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-021-00582-9
Chowdhury, I., Mishu, F. A., Alam, M. M., Yasmin, R., Rahman, M. M., & Mollah, F. H. (2021) · BIRDEM Medical Journal · doi:10.3329/birdem.v12i1.57219
Frisch, S., Jones, S. M., Willis, J., & Sinert, R. H. (2021) · doi:10.2196/preprints.29520
Farshidi, H., Hassaniazad, M., Hosseinpoor, M., Gharibzadeh, A., Nikpoor, A. R., Mohseni, S., Abbasi, H., Rafati, S., Madani, A., Zakeri, A.-J., et al. (2021) · Disease and Diagnosis · doi:10.34172/ddj.2021.27
Studie aus Oxford spricht für postinfektiöse Immunität
(2021) · Pneumologie · doi:10.1055/a-1473-1005
COVID-19 Course Depending on Serological Response to SARS-CoV-2
Матиевская, Н. В., Данилевич, Н. А., Кузнецова, Е. В., Сулевский, В. Н., Мовсумзаде, Л. А., & Красько, Ю. П. (2022) · Клиническая инфектология и паразитология · doi:10.34883/pi.2021.10.4.022
Hoover, S. E., & Reed, V. J. (2022) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2022.9
Lai, C., Potosky, A. L., McGuire, C., Lobo, T., Ahn, J., Haddad, B. R., Richards, E. W., Anand, P., Wright, K., Christenson, R. H., et al. (2022) · Journal of Oncology · doi:10.1155/2022/8798306
Anti-nucleocapsid Antibody Response After Two Doses of CoronaVac® Among Healthcare Workers
Toker, A. K., Özdemir, D. Ç., EREN, E. E., Özdemır, A. T., Kanat, A., Çelik, İ., & Toker, İ. (2022) · Mediterranean Journal of Infection Microbes and Antimicrobials · doi:10.4274/mjima.galenos.2022.2021.24
RELAÇÃO ESTRUTURA-ATIVIDADE DE FÁRMACOS ANTI-HIV DISPONIBILIZADOS PELO SISTEMA ÚNICO DE SAÚDE (SUS)
de Lira, M. F., de Melo, B. M. T., de Oliveira, L. L., Bezerra, C. D. O., Coutinho, F. N., & de Faria, A. R. (2022) · Latin American Publicações eBooks · doi:10.47174/lap2020.ed.00000107
DESAFIOS DO VÍRUS DA DENGUE NO MOSQUITO VETOR
Gonçalves, G. G. A., Feitosa, A. P. S., Brayner, F. A., & Alves, L. C. (2022) · Latin American Publicações eBooks · doi:10.47174/lap2020.ed.00000103
UMA BREVE ABORDAGEM DE LECTINA COM ATIVIDADE ANTI-SARS-CoV-2/COVID-19
Cintra, A. J. L., Torres‐León, C., Neves, J. L., & Correia, M. T. D. S. (2022) · Latin American Publicações eBooks · doi:10.47174/lap2020.ed.0000097
TERAPIAS ANTIVIRAIS: DA VACINA A NOVAS ABORDAGENS TERAPÊUTICAS
de Araújo, A. J. M., Bandeira, R. C. D. S., de Mélo, S. G. R., Calado, C. M. S. D. S., & Barbosa, A. V. (2022) · Latin American Publicações eBooks · doi:10.47174/lap2020.ed.00000109
Metadata
- Authors
- Lumley, S. F., O’Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth, A., Hatch, S. B., Marsden, B. D., Cox, S., James, T., Warren, F., Peck, L. J., Ritter, T. G., de Toledo, Z., Warren, L., Axten, D., Cornall, R. J., Jones, E. Y., Stuart, D. I., Screaton, G., Ebner, D., Hoosdally, S., Chand, M., Crook, D. W., O’Donnell, A.-M., Conlon, C. P., Pouwels, K. B., Walker, A. S., Peto, T. E. A., Hopkins, S., Walker, T. M., Jeffery, K., & Eyre, D. W.
- Affiliations
- Public Health England (GB)
- From Oxford University Hospitals NHS Foundation Trust (S.F.L., N.E.S., P.C.M., S.C., T.J., F.W., L.W., D.A., A.-M.O., K.J.), Nuffield Department of Medicine (S.F.L., D.O., N.E.S., P.C.M., A.H., S.B.H., B.D.M., R.J.C., E.Y.J., D.I.S., G.S., D.E., S. Hoosdally, D.W.C., C.P.C., A.S.W., T.E.A.P., T.M.W.), the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (N.E.S., P.C.M., S. Hoosdally, D.W.C., A.S.W., T.E.A.P., D.W.E.), the Kennedy Institute of Rheumatology Research (B.D...
- Corresponding author
- Eyre, David W.
- ORCID
- Lumley, Sheila F.
- Stoesser, Nicole E.
- Matthews, Philippa C.
- Hatch, Stephanie B.
- Marsden, Brian D.
- Peck, Liam J.
- Ritter, Thomas G.
- Cornall, Richard J.
- Stuart, David I.
- Screaton, Gavin
- Ebner, Daniel
- Hoosdally, Sarah
- Chand, Meera
- Crook, Derrick W.
- Conlon, Christopher P.
- Pouwels, Koen B.
- Walker, A. Sarah
- Peto, Tim E.A.
- Hopkins, Susan
- Jeffery, Katie
- Eyre, David W.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-11
- Volume
- 384
- Issue
- 6
- Pages
- 533-540
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7781098
- OpenAlex
- W3117382778
- Cited by
- 940
- References
- 29
- Citations by year
- 2026: 7 · 2025: 26 · 2024: 53 · 2023: 103 · 2022: 299 · 2021: 434
- FWCI
- 28.01
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- medRxiv (acceptedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- U.K. Government
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, COVID-19 reinfection, healthcare workers, anti-spike IgG, seropositivity, seroconversion, asymptomatic infection, symptomatic infection, infection incidence, antibody status
- MeSH terms
- Seroconversion, COVID-19, SARS-CoV-2, Coronavirus Nucleocapsid Proteins, COVID-19 Nucleic Acid Testing, COVID-19 Serological Testing, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Viral, Female, United Kingdom, Health Personnel, Humans, Immunoglobulin G, Longitudinal Studies, Male, Middle Aged, Recurrence, Incidence, Polymerase Chain Reaction, Young Adult, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review